1. Principal Investigator: SPARCo 1- Kumasi Site

Sickle Pan African Consortium: Establishing Sickle Cell Registry in African Countries: Tanzania, Nigeria and Ghana- (On-going April 2017-April 2021)

2. nvestigator: SPARCo 2- Kumasi Site

Sickle Pan African Consortium: Establishing Sickle Cell Registry in African Countries: Tanzania, Nigeria and Ghana- (On-going May 2021-April 2025)

3. Principal Investigator: HESTIA 3 ( 2019-2020)

              Protocol No.: D5136C00009

              Title: A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)

 4. Title: Organ Damage in Sickle Cell Disease (SCD): a study of the effects of complications of Sickle Cell Disease on end organs of people with SCD

 5. Protocol number: GBT2104-132 2021-

 Protocol title: “A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises”

6. Investigator: Educating mothers and primary caregivers to recognize the early clinical signs of pneumonia in children less than 2 years in Ghana: 2016-2017

7. Protocol number: GBT2104-131 (“Protocol”)

Title: “A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso- occlusive Crises” 

8. Protocol number: GBT2104-133 (“Protocol”)

Protocol title: “An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial”